Technical Analysis for PARDP - Poniard Pharm 2.4375 Pfd

Grade Last Price % Change Price Change
grade C 0.35 -12.50% -0.0500
PARDP closed down 12.5 percent on Friday, July 5, 2019, on 4.43 times normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A N/A
See historical PARDP trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Doji - Bullish? Reversal 0.00%
New 52 Week Low Weakness 0.00%
Gapped Down Weakness 0.00%
Narrow Range Bar Range Contraction -12.50%
Hot IPO Pullback Bullish Swing Setup -12.50%
Narrow Range Bar Range Contraction -12.50%
New 52 Week Closing Low Bearish -12.50%

Older signals for PARDP ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Chemistry RTT Cancer Biopharmaceutical Chemical Compounds Solid Tumors Prostate Cancer Cancer Therapy Treating Cancer Targeted Therapy Metastatic Colorectal Cancer Cancer Therapeutics Oncolytics Biotech
Is PARDP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 0 bearish and 5 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 0.59
52 Week Low 0.35
Average Volume 1,512
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 0.0
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0
MACD Signal Line 0.0
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.4100
Resistance 3 (R3) 0.4167 0.4033 0.4000
Resistance 2 (R2) 0.4033 0.3881 0.4000 0.3967
Resistance 1 (R1) 0.3767 0.3786 0.3700 0.3700 0.3933
Pivot Point 0.3633 0.3633 0.3600 0.3600 0.3633
Support 1 (S1) 0.3367 0.3481 0.3300 0.3300 0.3067
Support 2 (S2) 0.3233 0.3386 0.3200 0.3033
Support 3 (S3) 0.2967 0.3233 0.3000
Support 4 (S4) 0.2900